Sertraline and fluoxetine treatment of obsessive-compulsive disorder: Results of a double-blind, 6-month treatment study

Journal of Clinical Psychopharmacology

Volumn 22, Issue 2, 2002, Pages 148-154

  Bergeron, Richard ^a   Ravindran, Arun V ^a   Chaput, Yves ^a   Goldner, Elliot ^a   Swinson, Richard ^a   Van Ameringen, Michael A ^a   Austin, Carol ^a   Hadrava, Vratislav ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; SERTRALINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSESSION; OUTPATIENT CARE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SCORING SYSTEM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 0036214965     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200204000-00007     Document Type: Article

References (48)

1. Obsessive-compulsive disorder in the community: An epidemiologic survey with clinical reappraisal
2. The cross national epidemiology of obsessive compulsive disorder
3. Childhood-onset obsessive compulsive disorder
4. Obsessive-compulsive disorders and syndromes in the general population
5. Obsessive compulsive disorder
6. Obsessive-compulsive disorder
7. The epidemiology of obsessive-compulsive disorder in five US communities
8. Quality of life for patients with obsessive-compulsive disorder
9. Disability and family burden in obsessive-compulsive disorder
10. Obsessive-compulsive and spectrum disorders: Overview and quality of life issues
11. A pharmacoeconomic and quality of life study of OCD
12. Clomipramine in the treatment of obsessive-compulsive disorder
13. Efficacy of drug treatment in obsessive-compulsive disorder
14. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder
15. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder
16. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder
17. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder
18. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder
19. Efficacy of fluvoxamine in obsessive-compulsive disorder. A controlled clinical trial
20. Efficacy of fluvoxamine in obsessive-compulsive disorder: Results of a multicentre, double-blind, placebo-controlled trial
21. Sertraline in children and adolescents with obsessive-compulsive behavior; a multicenter randomized controlled trial
22. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder
23. Controlled comparison of clomipramine and fluoxetine in the treatment of obsessive compulsive disorder. Behavioral and biological results
24. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: A multicenter, randomized, double-blind, parallel group comparison
25. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison
26. Fluvoxamine v. clomipramine treatment in obsessive-compulsive disorder: A preliminary study
27. The Yale-Brown Obsessive-Compulsive Scale, II: Validity
28. The Yale-Brown Obsessive-Compulsive Scale: I: Development, use, and reliability
29. Methods for the quantitative assessment of depressive and manic behavior
30. A rating scale for depression
31. The Clinical Anxiety Scale: An instrument derived from the Hamilton Anxiety Scale
32. The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity
33. Reliability and validity of a health-related quality of life battery for evaluating out-patient antidepressant treatment
34. Patterns of remission and relapse in obsessive-compulsive disorder: A 2-year prospective study
35. Systematic review and guide to selection of selective serotonin reuptake inhibitors
36. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression
37. Selective serotonin reuptake inhibitors in the elderly: A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients
38. Pharmacokinetics of selective serotonin re-uptake inhibitors
39. Fluoxetine and norfluoxetine plasma concentrations in major depression: A multicenter study
40. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
41. An open trial of fluoxetine in the treatment of panic attacks
42. Pharmacological profile of antidepressants and related compounds at human monoamine transporters
43. A 1-year double-blind, placebo-controlled, fixed dose study of sertraline in the treatment of obsessive-compulsive disorder
44. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder
45. Continuation treatment of OCD: Double-blind and open-label experience with fluoxetine